# Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

> **NCT01703221** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 414 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Omarigliptin
- **DRUG:** Sitagliptin
- **DRUG:** Placebo to omarigliptin
- **DRUG:** Placebo to sitagliptin

## Key facts

- **NCT ID:** NCT01703221
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-24
- **Primary completion:** 2014-04-25
- **Final completion:** 2014-04-25
- **Target enrollment:** 414 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01703221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01703221, "Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01703221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*